Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials

Related

• 

  Episode 23: CANTREAT Study. Ranibizumab Monthly vs Treat-and-Extend for wAMD with Dr. Peter Kertes

  Keyvan Koushan, MD, FRCSC

  Member Podcasts

  2019

• 

  Expert Panel: Socioeconomics

  Linda A. Lam, MD, MBA, FASRS

  Ella H Leung, MD

  Mohsin H. Ali, MD

  Hasenin Al-khersan, MD

  Miguel A. Busquets, MD, FACS

  Annual Meeting Talks

  2024

• 

  Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian nAMD and DME Patients in a Real-World Setting: The PRECISE Study

  Ananda Kalevar, MD, FRCS(C), DABO

  On Demand Cases, Courses, and Papers

  2020